Replimune Group (REPL) Projected to Announce Quarterly Earnings on Thursday

Replimune Group (NASDAQ:REPL) is expected to announce its Q1 2027 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.6437) per share and revenue of $13.6010 million for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2027 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 7:00 AM ET.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Monday, June 29th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.10). On average, analysts expect Replimune Group to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Replimune Group Price Performance

NASDAQ REPL traded down $0.06 during trading on Tuesday, hitting $11.85. 2,393,062 shares of the stock traded hands, compared to its average volume of 4,944,250. The company has a quick ratio of 4.79, a current ratio of 4.79 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $995.84 million, a P/E ratio of -3.51 and a beta of 0.88. Replimune Group has a 12-month low of $1.50 and a 12-month high of $13.86. The firm has a 50-day simple moving average of $9.63 and a 200-day simple moving average of $7.41.

Analysts Set New Price Targets

A number of research firms recently issued reports on REPL. Weiss Ratings raised shares of Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 20th. Cantor Fitzgerald cut shares of Replimune Group from an “overweight” rating to a “hold” rating in a research note on Monday, April 13th. BMO Capital Markets upgraded shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 target price on the stock in a research report on Tuesday, June 30th. Wedbush upgraded Replimune Group from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $9.00 to $12.00 in a research report on Friday. Finally, JPMorgan Chase & Co. raised Replimune Group from a “neutral” rating to an “overweight” rating and set a $17.00 price objective on the stock in a research note on Friday, June 26th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.43.

Insider Buying and Selling at Replimune Group

In other news, insider Christopher Sarchi sold 12,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $9.24, for a total value of $110,880.00. Following the completion of the sale, the insider owned 180,962 shares in the company, valued at approximately $1,672,088.88. This trade represents a 6.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 5.40% of the company’s stock.

Institutional Trading of Replimune Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in REPL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Replimune Group by 17.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company’s stock worth $435,000 after buying an additional 6,653 shares during the period. Millennium Management LLC increased its stake in Replimune Group by 2.8% in the first quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock worth $11,927,000 after purchasing an additional 33,574 shares during the period. Goldman Sachs Group Inc. increased its stake in Replimune Group by 20.9% in the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock worth $6,729,000 after purchasing an additional 119,145 shares during the period. Rhumbline Advisers lifted its position in shares of Replimune Group by 6.9% during the second quarter. Rhumbline Advisers now owns 102,005 shares of the company’s stock worth $948,000 after purchasing an additional 6,616 shares during the last quarter. Finally, Sei Investments Co. boosted its stake in shares of Replimune Group by 149.5% during the second quarter. Sei Investments Co. now owns 30,478 shares of the company’s stock valued at $283,000 after purchasing an additional 18,263 shares during the period. 92.53% of the stock is owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.